If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
658.00    -19.00 (-2.81%)
Bid:
656.00
Ask:
660.00
Spread: 4.00 (0.61%)
Market Cap: £573.28m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Victrex Q3 Interim Management Statement

8 Jul 2020 07:00

RNS Number : 3159S
Victrex PLC
08 July 2020
 
 

 

 

8 July 2020

Victrex plc: Interim Management Statement

'Solid start but weaker end to Q3 as COVID headwinds impact performance'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its Interim Management Statement for the third quarter (Q3) covering the period 1 April to 30 June 2020.

Whilst Q3 started solidly, Victrex saw a weaker end to the quarter, as run-rates in May and June declined. On a year-to-date basis, Group volumes are broadly in line with the prior year. Margin was impacted during the quarter by the deferral of some elective procedures affecting our higher margin Medical business, as well as the under-absorption of fixed costs from lower production volumes. We expect these effects will continue to impact margin for the remainder of the second half.

 

Q3 and YTD performance

Overall, Q3 Group sales volume was down 12% to 805 tonnes (Q3 2019: 912 tonnes), with Group revenue down 18% to £58.8m (Q3 2019: £72.0m) reflecting mix as a key driver. On a year to date basis, (to the end of Q3) Group sales volume of 2,797 tonnes is broadly in line with the prior year (2019 YTD: 2,811 tonnes), with YTD Group revenue of £210.3m down 3% (YTD 2019: £217.8m).

Following a broadly stable performance in April, the months of May and June started to see the impact of COVID-19 related headwinds, with Group volume and revenue being more than 20% lower than the prior year. Aerospace, Automotive and Energy end-markets experienced the greatest level of decline, with performance being moderately weaker than market indicators. In Medical, the anticipated deferral of elective procedures started to impact us from April, with monthly revenue declines of up to 40% in this division, although market indicators suggest procedure deferral will gradually reverse. Pleasingly, the gradual return of some elective surgeries in Asia and continued growth in non-Spine has kept year-to-date Medical revenues ahead of the prior year in that region.

 

Mega-programme progress

As part of its Polymer & Parts strategy, Victrex continues to focus on delivering further milestones in its growth pipeline, as well as exploring options to drive growth within the PAEK family of polymers or related technologies. Whilst we are mindful that COVID-19 may lead to some delays in achievement of milestones in certain projects, and are monitoring developments closely, overall our growth pipeline is progressing broadly as planned, with the long-term value proposition for the use of PEEK remaining strong.

 

In Magma, testing data points from Technip FMC have indicated PEEK as the preferred material of choice for the demanding conditions in Brazil. This follows Victrex manufacturing the 6-inch PEEK liner pipe, as well as the supply of PEEK composite tape in support of Technip FMC's qualification programme. Additional opportunities outside of Brazil remain under discussion.

 

In Medical, the clinical trial for our Knee programme in Italy has resumed, with the first patient implant expected around the end of our financial year, with additional trials in Europe and Asia being explored, to drive commercialisation. We continue to see good opportunities in Asia, both in Spine and non-Spine, particularly in CMF, Trauma and Arthroscopy.

 

Financial position and cost management

Our net cash position at 30 June 2020 was slightly ahead of our expectations at £72m, which includes approximately £8m ring-fenced for our China manufacturing subsidiary. The Group has an undrawn and committed RCF of £20m, together with a £20m accordion facility.

 

The Group is also reflecting the weaker demand Outlook through the remainder of FY 2020 and into H1 2021, as well as the ongoing impact of under-absorption of fixed costs, by reviewing additional cost actions, to support profitability in a lower production environment.

 

As previously communicated, we will assess macro and end market conditions later in the year, and the Outlook for FY 2021, before making a declaration on dividends for FY 2020.

 

Outlook

With an additional impact in our current and forward order book from COVID-related headwinds, and with macro and end market uncertainty, as previously communicated, we are unable to provide detailed guidance on full year expectations.

 

With lower production levels reflecting weaker demand and planned inventory reduction, and consequently the under-absorption of fixed costs, together with a weaker mix, margin is anticipated to be further impacted in the second half and into FY 2021. Whilst market indicators may remain negative across many of our end-markets as we move into our next financial year, we anticipate being in a better position later in the year to assess the Outlook.

 

Our focus continues to be on the safety, health and well-being of our employees, delivering good customer service and managing our costs. Whilst we have already carried out a number of cash conservation measures, further actions are being considered should there be a sustained downturn. Overall, with sustainable products, our range of medium to long term growth opportunities remain strong, our financial position is robust and our cash generation capabilities offer the opportunity of good medium term returns to shareholders.

 

Analyst & investor conference call

A conference call for analysts & investors will be held today, 8 July, at 08.30am BST.

Dial in details: +44 (0) 3333 000804 PIN: 57293642#

Victrex plc:

Andrew Hanson, Director of Investor Relations & Communications +44 (0) 7809 595831

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

Richard Armitage, Chief Financial Officer +44 (0) 1253 897700

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy (including manufacturing & engineering), electronics and medical. Every day, millions of people use products and applications, which contain our materials - from smart phones, aeroplanes and cars to oil and gas operations and medical devices. With over 40 years' experience, we develop world leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTRRMRTMTJMBMM
Date   Source Headline
8th Feb 201210:33 amRNSResult of AGM
7th Feb 20127:00 amRNSAGM and Interim Management Statement
31st Jan 20123:02 pmRNSTotal Voting Rights
17th Jan 20123:28 pmRNSDirector/PDMR Shareholding
4th Jan 20121:38 pmRNSAnnual Information Update
4th Jan 201211:35 amRNSAnnual Financial Report
3rd Jan 201211:23 amRNSHolding(s) in Company
30th Dec 201112:00 pmRNSTotal Voting Rights
19th Dec 201112:00 pmRNSDirector/PDMR Shareholding
13th Dec 20113:43 pmRNSDirector/PDMR Shareholding
6th Dec 20117:00 amRNSFinal Results
1st Dec 201111:24 amRNSBlocklisting Interim Review
30th Nov 201111:48 amRNSTotal Voting Rights
17th Nov 201111:43 amRNSDirector/PDMR Shareholding
2nd Nov 20114:22 pmRNSHolding(s) in Company
31st Oct 20111:52 pmRNSTotal Voting Rights
19th Oct 20111:45 pmRNSDirector/PDMR Shareholding
6th Oct 20113:27 pmRNSHolding(s) in Company
6th Oct 20117:02 amRNSDirectorate Change
6th Oct 20117:00 amRNSYear End Trading Update
30th Sep 20112:14 pmRNSTotal Voting Rights
19th Sep 20114:22 pmRNSDirector/PDMR Shareholding
6th Sep 20112:52 pmRNSHolding(s) in Company
31st Aug 20113:38 pmRNSTotal Voting Rights
17th Aug 20113:26 pmRNSDirector/PDMR Shareholding
10th Aug 201110:48 amRNSHolding(s) in Company
4th Aug 20117:00 amRNSInterim Management Statement
29th Jul 20113:52 pmRNSTotal Voting Rights
29th Jul 20112:05 pmRNSHolding(s) in Company
19th Jul 20113:59 pmRNSHolding(s) in Company
19th Jul 20111:40 pmRNSDirector/PDMR Shareholding
4th Jul 20114:09 pmRNSHolding(s) in Company
1st Jul 20111:23 pmRNSTotal Voting Rights Replacement
30th Jun 20113:38 pmRNSDirector/PDMR Shareholding
27th Jun 20111:47 pmRNSHolding(s) in Company
17th Jun 20112:21 pmRNSDirector/PDMR Shareholding
8th Jun 20113:55 pmRNSDirector/PDMR Shareholding
1st Jun 201111:07 amRNSBlocklisting Interim Review
1st Jun 201111:01 amRNSTotal Voting Rights
24th May 20117:00 amRNSHalf Yearly Report
18th May 20112:20 pmRNSDirector/PDMR Shareholding
6th May 20112:53 pmRNSHolding(s) in Company
5th May 20114:22 pmRNSHolding(s) in Company
4th May 20113:00 pmRNSTotal Voting Rights
4th May 20112:51 pmRNSHolding(s) in Company
19th Apr 20112:44 pmRNSDirector/PDMR Shareholding
7th Apr 20117:00 amRNSTrading Update
1st Apr 201111:00 amRNSTotal Voting Rights
25th Mar 20111:59 pmRNSDirector Declaration
17th Mar 20112:44 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.